Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Carl Eriksson

Showing results (41-50 of 58) with videos related to

Pageof 6
Sort By:
Learning Health Systems|June 8, 2026
RescueGPT: An Automated System for Detecting Adverse Safety Events in Prehospital Emergency Medical Service Notes With a Zero-Shot Approach With Large Language Models: A Proof-of-Concept StudyTina Yi Jin Hsieh, Carl Eriksson, Garth Meckler, et al.
Medrxiv : the Preprint Server for Health Sciences|December 25, 2025
A medically grounded LLM agent-based tool to detect patient safety events in medical records: Identifying patient safety events with large language modelsDiego Trujillo, Dulin Wang, Nathan Bahr, et al.
Therapeutic Advances in Gastroenterology|June 5, 2023
Long-term outcomes of vedolizumab in inflammatory bowel disease: the Swedish prospective multicentre SVEAH extension studyIsabella Visuri, Carl Eriksson, Sara Karlqvist, et al.
Gastroenterology|July 23, 2021
Systemic Inflammation in Preclinical Ulcerative ColitisDaniel Bergemalm, Erik Andersson, Johan Hultdin, et al.
Scandinavian Journal of Gastroenterology|April 1, 2017
Long-term effectiveness of vedolizumab in inflammatory bowel disease: a national study based on the Swedish National Quality Registry for Inflammatory Bowel Disease (SWIBREG)Carl Eriksson, Jan Marsal, Daniel Bergemalm, et al.
Therapeutic Advances in Gastroenterology|July 19, 2021
Real-world effectiveness of vedolizumab in inflammatory bowel disease: week 52 results from the Swedish prospective multicentre SVEAH studyCarl Eriksson, Sara Rundquist, Vyron Lykiardopoulos, et al.
Prehospital Emergency Care|February 5, 2025
EMS Agency Characteristics and Adverse Events in Pediatric Out-of-Hospital Cardiac Arrest Among 49 U.S. EMS AgenciesMatthew L Hansen, Grace Walker-Stevenson, Nathan Bahr, et al.
Gastroenterology|November 28, 2024
Preclinical Protein Signatures of Crohn's Disease and Ulcerative Colitis: A Nested Case-Control Study Within Large Population-Based CohortsOlle Grännö, Daniel Bergemalm, Benita Salomon, et al.
Alimentary Pharmacology & Therapeutics|November 7, 2019
Pregnancy outcomes in inflammatory bowel disease patients treated with vedolizumab, anti-TNF or conventional therapy: results of the European CONCEIVE studyAnnick Moens, C Janneke van der Woude, Mette Julsgaard, et al.
Scandinavian Journal of Gastroenterology|May 7, 2020
The use of ICD codes to identify IBD subtypes and phenotypes of the Montreal classification in the Swedish National Patient RegisterSarita Shrestha, Ola Olén, Carl Eriksson, et al.
Pageof 6

Showing results (41-50 of 58) with videos related to

Sort By:
Pageof 6
Learning Health Systems|June 8, 2026
RescueGPT: An Automated System for Detecting Adverse Safety Events in Prehospital Emergency Medical Service Notes With a Zero-Shot Approach With Large Language Models: A Proof-of-Concept StudyTina Yi Jin Hsieh, Carl Eriksson, Garth Meckler, et al.
Medrxiv : the Preprint Server for Health Sciences|December 25, 2025
A medically grounded LLM agent-based tool to detect patient safety events in medical records: Identifying patient safety events with large language modelsDiego Trujillo, Dulin Wang, Nathan Bahr, et al.
Therapeutic Advances in Gastroenterology|June 5, 2023
Long-term outcomes of vedolizumab in inflammatory bowel disease: the Swedish prospective multicentre SVEAH extension studyIsabella Visuri, Carl Eriksson, Sara Karlqvist, et al.
Gastroenterology|July 23, 2021
Systemic Inflammation in Preclinical Ulcerative ColitisDaniel Bergemalm, Erik Andersson, Johan Hultdin, et al.
Scandinavian Journal of Gastroenterology|April 1, 2017
Long-term effectiveness of vedolizumab in inflammatory bowel disease: a national study based on the Swedish National Quality Registry for Inflammatory Bowel Disease (SWIBREG)Carl Eriksson, Jan Marsal, Daniel Bergemalm, et al.
Therapeutic Advances in Gastroenterology|July 19, 2021
Real-world effectiveness of vedolizumab in inflammatory bowel disease: week 52 results from the Swedish prospective multicentre SVEAH studyCarl Eriksson, Sara Rundquist, Vyron Lykiardopoulos, et al.
Prehospital Emergency Care|February 5, 2025
EMS Agency Characteristics and Adverse Events in Pediatric Out-of-Hospital Cardiac Arrest Among 49 U.S. EMS AgenciesMatthew L Hansen, Grace Walker-Stevenson, Nathan Bahr, et al.
Gastroenterology|November 28, 2024
Preclinical Protein Signatures of Crohn's Disease and Ulcerative Colitis: A Nested Case-Control Study Within Large Population-Based CohortsOlle Grännö, Daniel Bergemalm, Benita Salomon, et al.
Alimentary Pharmacology & Therapeutics|November 7, 2019
Pregnancy outcomes in inflammatory bowel disease patients treated with vedolizumab, anti-TNF or conventional therapy: results of the European CONCEIVE studyAnnick Moens, C Janneke van der Woude, Mette Julsgaard, et al.
Scandinavian Journal of Gastroenterology|May 7, 2020
The use of ICD codes to identify IBD subtypes and phenotypes of the Montreal classification in the Swedish National Patient RegisterSarita Shrestha, Ola Olén, Carl Eriksson, et al.
Pageof 6